Small Business Innovation Research (SBIR) to Develop New Methods and Technologies for Assessment of Risk and for Early Diagnosis and Prognosis of Type 1 Diabetes
| Jurisdiction: |
Federal
|
| Incentive Type: | Grant Program |
| Industries: |
Medical, Food, Health And Safety
|
| Eligible Sector: |
Business
|
| Category: |
Financial Incentive
|
| Time Period: |
FY 2015
|
| Governing Body: | National Institutes of Health |
| What’s it worth?: | $2,000,000 |
The Small Business Innovation Research (SBIR) to Develop New Methods and Technologies for Assessment of Risk and for Early Diagnosis and Prognosis of Type 1 Diabetes program provides funding for type 1 diabetes early detection and risk assessments for early diagnosis, prognosis and follow-up research. Relevant topics include the development of:
- Prediction, prevention, progression of diabetes techniques or products
- High-throughput assays for autoantibody detection markers for diagnosis and follow-up
- Point-of-care low-cost portable devices for at risk or diagnosis of diabetes
- Methods to measure changes in the immune status
- Non-invasive imaging
- High-throughput assays based on biologic pathways
There are three types of applications allowed: New proposals (Phase I), Renewal grants (Phase II) and Resubmission applications. $2,000,000 is available for allocation into four to eight awards with typical award amounts of not more than $225,000 for Phase I projects and up to $1,500,000 for Phase II projects with project duration of up to two years.
